Hematopoietic Stem Cell Transplantation (HSCT) is an effective treatment for malignant hematological tumors. One of the key factors determining the success of HSCT is Human Leukocyte Antigen (HLA) matching. If the HLA of the donor and the patient (recipient) do not match, severe rejection may occur, even endangering life.

Zhou Zhou from Guangxi is a patient with severe β-thalassemia. After 16 years of blood transfusion, she and her family decided to undergo hematopoietic stem cell transplantation (HSCT). In 2021, the soon-to-be 17-year-old Zhou Zhou found the team led by Director Liao Jianyun. After two years of continuous iron chelation therapy, she underwent HSCT at Southern Chunfu (Children's) Institute of Hematology, Gobroad Medical (Hematology) Guangdong Research Center in 2023.